JPWO2021021986A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021021986A5
JPWO2021021986A5 JP2022506169A JP2022506169A JPWO2021021986A5 JP WO2021021986 A5 JPWO2021021986 A5 JP WO2021021986A5 JP 2022506169 A JP2022506169 A JP 2022506169A JP 2022506169 A JP2022506169 A JP 2022506169A JP WO2021021986 A5 JPWO2021021986 A5 JP WO2021021986A5
Authority
JP
Japan
Prior art keywords
carboxamide
imidazol
alkyl
pyrimidine
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542396A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044156 external-priority patent/WO2021021986A1/en
Publication of JP2022542396A publication Critical patent/JP2022542396A/ja
Publication of JPWO2021021986A5 publication Critical patent/JPWO2021021986A5/ja
Pending legal-status Critical Current

Links

JP2022506169A 2019-07-31 2020-07-30 Cd38の阻害剤としてのヘテロ二環式アミド Pending JP2022542396A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880923P 2019-07-31 2019-07-31
US62/880,923 2019-07-31
US201962951604P 2019-12-20 2019-12-20
US62/951,604 2019-12-20
US202063034750P 2020-06-04 2020-06-04
US63/034,750 2020-06-04
PCT/US2020/044156 WO2021021986A1 (en) 2019-07-31 2020-07-30 Heterobicyclic amides as inhibitors of cd38

Publications (2)

Publication Number Publication Date
JP2022542396A JP2022542396A (ja) 2022-10-03
JPWO2021021986A5 true JPWO2021021986A5 (es) 2023-08-07

Family

ID=72139677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506169A Pending JP2022542396A (ja) 2019-07-31 2020-07-30 Cd38の阻害剤としてのヘテロ二環式アミド

Country Status (12)

Country Link
US (2) US11535621B2 (es)
EP (1) EP4003980A1 (es)
JP (1) JP2022542396A (es)
KR (1) KR20220061958A (es)
CN (1) CN114423753A (es)
AU (1) AU2020321956A1 (es)
BR (1) BR112022001291A2 (es)
CA (1) CA3147902A1 (es)
IL (1) IL289878A (es)
MX (1) MX2022001019A (es)
TW (1) TW202120496A (es)
WO (1) WO2021021986A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542396A (ja) 2019-07-31 2022-10-03 ライボン・セラピューティクス・インコーポレイテッド Cd38の阻害剤としてのヘテロ二環式アミド
WO2022165114A1 (en) 2021-01-29 2022-08-04 Ribon Therapeutics, Inc. Quinolines and azaquinolines as inhibitors of cd38
CN117813296A (zh) * 2021-07-12 2024-04-02 赛特凯恩蒂克公司 Cd38调节剂和其使用方法
WO2023084206A1 (en) 2021-11-09 2023-05-19 Cerevance Ltd N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors
CN114306366B (zh) * 2021-11-30 2023-01-06 合肥康诺生物制药有限公司 含nad和cd38抑制剂的药物组合物及其用途
WO2023098699A1 (en) * 2021-12-01 2023-06-08 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
GB202207721D0 (en) * 2022-05-25 2022-07-06 Cerevance Ltd Novel Compounds
KR20240020201A (ko) * 2022-08-05 2024-02-14 주식회사 넥스트젠바이오사이언스 저산소증 유도 인자 1(hif-1) 억제제 또는 혈관내피성장인자(vegf)억제제 로서의 신규 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666624C (en) * 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8765792B2 (en) * 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
MY183661A (en) * 2011-10-19 2021-03-05 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
RU2621148C2 (ru) * 2011-11-04 2017-05-31 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Способ лечения
NZ628410A (en) * 2012-02-24 2016-03-31 Signal Pharm Llc Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
KR20170090478A (ko) 2014-12-03 2017-08-07 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Cd38 억제제 및 치료 방법
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
EP3687529B1 (en) * 2017-09-27 2023-07-12 The Regents of the University of California Potent antiviral pyridine-containing compounds
JP2022542396A (ja) 2019-07-31 2022-10-03 ライボン・セラピューティクス・インコーポレイテッド Cd38の阻害剤としてのヘテロ二環式アミド
US20230025807A1 (en) 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
IL297128A (en) 2020-04-07 2022-12-01 Mitobridge Inc cd38 inhibitors
WO2022165114A1 (en) 2021-01-29 2022-08-04 Ribon Therapeutics, Inc. Quinolines and azaquinolines as inhibitors of cd38

Similar Documents

Publication Publication Date Title
US20220241261A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
US9795607B2 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JP5167291B2 (ja) ジヒドロピラゾロピリミジノン誘導体
JP2019504821A5 (es)
ES2373688T3 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas janus.
JP2018522859A5 (es)
US10023576B2 (en) Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
TW201840549A (zh) 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺
JP2013523884A5 (es)
JPWO2009054332A1 (ja) ピリドン置換ジヒドロピラゾロピリミジノン誘導体
US10214537B2 (en) Bicyclic heteroaryl amine compounds
EA030376B1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
TW202200552A (zh) 作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑
US10894784B2 (en) Heteroarylbenzimidazole compounds
TW202116753A (zh) 以噌啉作為hpk1的抑制劑
US20230406860A1 (en) Heterocyclic spiro compounds and methods of use
JPWO2021021986A5 (es)
US20240150356A1 (en) Pyrimidine amide compounds and use thereof